Loading...
Docoh

Precision Biosciences (DTIL)

News

From Benzinga Pro
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 May 22
Pre-Market Outlook, Markets, Movers
Precision BioSciences: Q1 Earnings Insights
9 May 22
Earnings, News
Precision BioSciences (NASDAQ:DTIL) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Precision BioSciences Q1 EPS $(0.46) Beats $(0.55) Estimate, Sales $3.30M Miss $6.63M Estimate
9 May 22
Earnings, News
Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.55) by 16.36 percent. This is a 39.39 percent decrease over losses of $(0.33) per share
Earnings Scheduled For May 9, 2022
9 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Preview: Precision BioSciences's Earnings
6 May 22
Earnings
Precision BioSciences (NASDAQ:DTIL) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Precision BioSciences will report an earnings per share (EPS) of $-0.55.
Stocks That Hit 52-Week Lows On Friday
6 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 1043 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
28 Apr 22
News, Options, Intraday Update, Markets
During Thursday, 849 stocks hit new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
27 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
Wednesday's session saw 784 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
26 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Stocks That Hit 52-Week Lows On Monday
25 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 721 companies achieved new lows for the year.
Stocks That Hit 52-Week Lows On Friday
22 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 431 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
19 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Tuesday, 242 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
18 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 466 companies hit new 52-week lows.
66 Biggest Movers From Yesterday
23 Mar 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers JX Luxventure Limited (NASDAQ: LLL) shares jumped 119.5% to settle at $4.39 on Tuesday after the company announced it signed a $60 million sales agreement.
42 Stocks Moving In Tuesday's Mid-Day Session
22 Mar 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Forge Global Holdings Inc. (NYSE: FRGE) shares jumped 67.7% to $16.95. True Global Ventures’ portfolio company Forge Global Holdings completed its business combination with Motive Capital Corp on the 22nd of March, 2022.
Precision BioSciences Granted U.S. Patent #11,278,632 Engineered nucleases useful for treatment of hemophilia A
22 Mar 22
News
View patent here
Lannett And 4 Other Penny Stocks Bought By Insiders
22 Mar 22
Long Ideas, News, Penny Stocks, Insider Trades, Markets, Trading Ideas
US stock futures traded higher this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Stocks That Hit 52-Week Lows On Wednesday
16 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Wednesday, 90 companies set new 52-week lows.
Looking Into Precision BioSciences's Return On Capital Employed
16 Mar 22
Earnings
Precision BioSciences (NASDAQ:DTIL) brought in sales totaling $6.34 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 97.62%, resulting in a loss of $22.29 million.
Goldman Sachs Maintains Neutral on Precision BioSciences, Lowers Price Target to $5
16 Mar 22
News, Price Target, Analyst Ratings
Goldman Sachs maintains Precision BioSciences (NASDAQ:DTIL) with a Neutral and lowers the price target from $12 to $5.

Press releases

From Benzinga Pro
Precision BioSciences Appoints Juli Blanche as Chief People Officer
23 May 22
Press Releases
New Senior Executive Brings 25 Years of Human Resources Leadership and Pharma Industry Experience Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo
Precision BioSciences Announces Publication in Molecular Therapy of ARCUS® In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection
18 May 22
Press Releases
- ARCUS Genome Editing Achieved Substantial Reductions in both cccDNA and Hepatitis B Surface Antigen (HBsAg), 85% and 77% respectively, in HBV-infected Primary Human Hepatocytes (PHH) - Significant Decrease in HBsAg
Precision BioSciences Announces Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities at American Society of Gene & Cell Therapy Annual Meeting
16 May 22
Press Releases
Multiple Oral Presentations and Posters to Demonstrate Differentiated Attributes of ARCUS® Genome Editing Platform for Efficient Gene Insertion and Gene Knockout New Primary Hyperoxaluria Type 1 (PH1) Preclinical
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
12 May 22
Press Releases
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on May 6, 2022, the
Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update
9 May 22
Press Releases
- PBCAR0191, PBCAR19B and PBCAR269A Allogeneic CAR T Program Updates Planned for June 2022 - Three Wholly Owned In Vivo Gene Editing Programs Progressing Toward IND or CTA in the Next Three Years - Preclinical In Vivo
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cell Therapy 25th Annual Meeting
2 May 22
Press Releases
- Accepted abstracts to be presented as oral presentations and posters highlight preclinical development progress for ARCUS® gene editing therapies Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
15 Mar 22
Press Releases
- Advancing ARCUS® Platform by Developing In Vivo Gene Editing Programs for Genetic Diseases and Ex Vivo CAR T Therapies for Hematologic Malignancies - Presented Allogeneic CAR T Clinical Data at the American
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2021 Results on March 15, 2022
8 Mar 22
Press Releases
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial